Hwa Young Lee1, Deok Jae Han1, Kyung Joo Kim1, Tae Hoon Kim2, Yeon-Mok Oh3, Chin Kook Rhee1. 1. Division of Pulmonary and Critical Care Medicine, Department of Internal medicine, The Catholic University of Korea, Seoul, Korea. 2. Department of Internal medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea. 3. Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Tuberculous destroyed lung (TDL) contributes to patient mortality via acute exacerbation and combined medical comorbidities. This study characterized the clinical characteristics and economic burden of patients with TDL using large scale database, Health Insurance Review and Assessment Service (HIRA) data. METHODS: We searched the HIRA national database to identify patients diagnosed with TDL from January 01, 2011 to December 31, 2015. The clinical characteristics of the patients were collected and the 5-year claims data were analyzed. RESULTS: In total, 645,031 patients (55% male, mean age, 59.6 years) were enrolled over the 5 years. During the study period, 98.5% of the patients visited a primary care clinic and 71.1% and 93.2% visited secondary and tertiary hospitals, respectively. Patients spent a median of 5 days for inpatient services, and were admitted to the hospital a median of 0.62±1.2 times per person annually. Annual total cost per person was $1,838 and half of the total cost was expended for inpatient services. About 68.9% of the patients were prescribed respiratory medications, and $12 million was paid. Oral bronchodilators (46.5%) and methylxanthine (35.2%) were used more frequently than inhaled corticosteroids (ICSs)/long-acting β2 agonist (LABA) combination agents (11.6%) or inhaled long-acting muscarinic antagonists (LAMAs) (7.5%). CONCLUSIONS: TDL imposes a high medical economic burden in Korea. The estimated economic costs were mainly made up of inpatient services and outpatient medication prescriptions. Interventions to prevent acute disease exacerbations and progression of comorbid conditions should be accompanied to alleviate the clinical and economic burden of TDL.
BACKGROUND: Tuberculous destroyed lung (TDL) contributes to patient mortality via acute exacerbation and combined medical comorbidities. This study characterized the clinical characteristics and economic burden of patients with TDL using large scale database, Health Insurance Review and Assessment Service (HIRA) data. METHODS: We searched the HIRA national database to identify patients diagnosed with TDL from January 01, 2011 to December 31, 2015. The clinical characteristics of the patients were collected and the 5-year claims data were analyzed. RESULTS: In total, 645,031 patients (55% male, mean age, 59.6 years) were enrolled over the 5 years. During the study period, 98.5% of the patients visited a primary care clinic and 71.1% and 93.2% visited secondary and tertiary hospitals, respectively. Patients spent a median of 5 days for inpatient services, and were admitted to the hospital a median of 0.62±1.2 times per person annually. Annual total cost per person was $1,838 and half of the total cost was expended for inpatient services. About 68.9% of the patients were prescribed respiratory medications, and $12 million was paid. Oral bronchodilators (46.5%) and methylxanthine (35.2%) were used more frequently than inhaled corticosteroids (ICSs)/long-acting β2 agonist (LABA) combination agents (11.6%) or inhaled long-acting muscarinic antagonists (LAMAs) (7.5%). CONCLUSIONS: TDL imposes a high medical economic burden in Korea. The estimated economic costs were mainly made up of inpatient services and outpatient medication prescriptions. Interventions to prevent acute disease exacerbations and progression of comorbid conditions should be accompanied to alleviate the clinical and economic burden of TDL.
Authors: C K Rhee; K H Yoo; J H Lee; M J Park; W J Kim; Y B Park; Y I Hwang; Y S Kim; J Y Jung; J Y Moon; Y K Rhee; H K Park; J H Lim; H Y Park; S W Lee; Y H Kim; S H Lee; H K Yoon; J W Kim; J S Kim; Y K Kim; Y M Oh; S D Lee; H J Kim Journal: Int J Tuberc Lung Dis Date: 2013-01 Impact factor: 2.373
Authors: JinHee Kim; Chin Kook Rhee; Kwang Ha Yoo; Young Sam Kim; Sei Won Lee; Yong Bum Park; Jin Hwa Lee; YeonMok Oh; Sang Do Lee; Yuri Kim; KyungJoo Kim; HyoungKyu Yoon Journal: Int J Chron Obstruct Pulmon Dis Date: 2013-11-19